Page last updated: 2024-10-28

hydroxyurea and Cancer of Head

hydroxyurea has been researched along with Cancer of Head in 107 studies

Research Excerpts

ExcerptRelevanceReference
" In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected."3.75Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. ( Glick, JH; Taylor, SG; Zehngebot, LM, 1980)
"Eligible patients had newly diagnosed HNSCC."2.76A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011)
"Eligibility criteria were recurrence or a second primary tumor in a previously irradiated area, no major sequelae resulting from the first radiotherapy, good general condition, no distant metastasis, and salvage surgery with macroscopic complete resection."2.73Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008)
"Hydroxyurea (HU) has been associated with fewer irreversible toxicities."2.73Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase in ( Beitler, JJ; Mazumdar, M; Owen, RP; Silver, CE; Smith, RV; Wadler, S, 2007)
"Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible."2.73Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008)
"Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy."2.72High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. ( Brockstein, B; Cohen, EE; Haraf, DJ; Kies, MS; Kocherginsky, M; List, MA; Mittal, BB; Rosen, F; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2006)
"Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible."2.71Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. ( Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE, 2004)
"The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery."2.70Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001)
"Patients with recurrent squamous cell cancer of the head and neck (SCH&N) are generally treated with systemic chemotherapy."2.70RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. ( Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2001)
"To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy."2.69Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000)
"The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease."2.68Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997)
"The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy."2.67Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992)
"Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea."2.67Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991)
"Hydroxyurea was substituted for bleomycin when the accumulative dose of bleomycin reached 400 units."2.65Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma. ( Gonzalez, MF; Sartiano, GP; Valdivieso, JG, 1984)
"The systemic therapy of head and neck cancer has gained momentum in recent years."2.42Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. ( Argiris, A; Haraf, DJ; Kies, MS; Vokes, EE, 2003)
"At diagnosis of head and neck cancer, over half of all patients show advanced stages."2.40[Chemoradiotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 1997)
"The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)."2.40Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998)
"This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities."2.35Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975)
"We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database."1.46Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. ( Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS, 2017)
"In this study, using HNSCC cell lines, we examined the anti-cancer effects and the mechanisms of action of docosahexaenoyl ethanolamide (DHEA) and N-arachidonoyl-L-alanine (NALA), which are polyunsaturated fatty acid (PUFA)-based ethanolamides like AEA."1.435-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells. ( Hah, JH; Jeong, WJ; Oh, SM; Park, SW; Sung, MW, 2016)
"Skin cancer is the most common cancer, and often occurs in the head and neck region."1.35Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009)
"Locoregionally advanced, stage IV head and neck cancer has traditionally carried a poor prognosis."1.32Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. ( Brockstein, B; Fung, BB; Haraf, DJ; Kies, MS; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, F; Stenson, KM; Vokes, EE; Weichselbaum, RW; Wenig, B; Witt, ME, 2004)
"Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects."1.30Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999)
"Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem."1.28Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992)
"A cohort of 26 patients with head and neck cancer of all histologies were entered into a broad phase I study investigating simultaneous radiation therapy, 5-FU (with or without leucovorin), HU, and infusional cisplatin administered on an alternate-week schedule."1.28Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992)
"Hydroxyurea is an active single agent in squamous cell cancer of the head and neck."1.28Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992)
"Patients with cancer of nasopharynx had a better survival than those with other primaries (P = 0."1.28Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. ( Daniilidis, J; Destouni-Salem, E; Fountzilas, G; Kalogera-Fountzila, A; Sombolos, K; Sridhar, KS; Tourkantonis, A; Vritsios, A; Zaramboukas, T, 1990)
"Sixty-six patients with advanced head and neck cancer 57 of whom had failed to respond to prior irradiation, were treated according to two protocols."1.26[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. ( Asselin, B; Bataini, JP; Brugère, J; Garcia-Giralt, E; Jaulerry, M; Jouve, M; Palangie, T; Pouillart, P, 1980)
"Thirty-two patients with squamous cell carcinoma of head and neck not amenable to surgery or radiotherapy were treated with a combination of methotrexate 0."1.26Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea. ( Alberto, P; Lehmann, W; Medenica, R, 1981)
"Ffty-three patients with head and neck cancer tested before radiation treatment to determine numbers of blood lymphocytes and immunologic responses to mitogens of lymphocytes in whole-blood cultures had mean values that were 19% to 26% less than values for healthy individuals."1.26Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy. ( Ellis, HN; Griffiths, CM; Jenkins, VK; Olson, MH; Perry, RR; Ray, P, 1976)

Research

Studies (107)

TimeframeStudies, this research(%)All Research%
pre-199042 (39.25)18.7374
1990's30 (28.04)18.2507
2000's25 (23.36)29.6817
2010's9 (8.41)24.3611
2020's1 (0.93)2.80

Authors

AuthorsStudies
Rubin, A1
Haroon, A1
Rao, BK1
Firoz, BF1
Cohen, EE8
Karrison, TG1
Kocherginsky, M3
Mueller, J1
Egan, R1
Huang, CH1
Brockstein, BE7
Agulnik, MB1
Mittal, BB10
Yunus, F1
Samant, S1
Raez, LE1
Mehra, R1
Kumar, P1
Ondrey, F1
Marchand, P1
Braegas, B1
Seiwert, TY5
Villaflor, VM2
Haraf, DJ32
Vokes, EE40
Sachdev, S1
Refaat, T1
Bacchus, ID1
Sathiaseelan, V1
Park, SW1
Hah, JH1
Oh, SM1
Jeong, WJ1
Sung, MW1
Chen, JH1
Yen, YC1
Chen, TM1
Yuan, KS1
Lee, FP1
Lin, KC1
Lai, MT1
Wu, CC1
Chang, CL1
Wu, SY1
Salama, JK5
Stenson, KM6
Kistner, EO1
Argiris, A3
Witt, ME15
Rosen, F4
Janot, F3
de Raucourt, D1
Benhamou, E1
Ferron, C1
Dolivet, G1
Bensadoun, RJ1
Hamoir, M1
Géry, B1
Julieron, M2
Castaing, M1
Bardet, E1
Grégoire, V1
Bourhis, J2
Fegn, L1
Wang, Z1
Kao, J3
Genden, EM2
Gupta, V2
Policarpio, EL1
Burri, RJ1
Rivera, M2
Gurudutt, V2
Som, PM1
Teng, M1
Packer, SH2
Blair, EA4
Williams, R2
Kunnavakkam, R1
Seiwert, T1
Choe, KS1
Solanki, A1
Portugal, L6
Tong, CC1
Lau, KH1
Cannan, D1
Aguirre-Ghiso, J1
Sikora, AG1
Forsythe, K1
Ko, EC1
Misiukiewicz, K1
Teng, MS1
Darga, T1
Haraf, D2
Stenson, K13
Villaflor, V1
Lingen, MW1
Weichselbaum, RR24
Spencer, S1
Wheeler, R1
Peters, G1
Meredith, R3
Beenken, S1
Nabel, L1
Wooten, A1
Soong, SJ1
Salter, M1
Rosen, FR3
Kies, MS8
Rademaker, AW5
List, MA4
Fung, BB2
Pelzer, H9
Yang, WL1
Yang-Biggs, G1
Wu, Y1
Ye, X1
Gallos, G1
Owen, RP2
Ravikumar, TS1
Garden, AS1
Harris, J3
Forastiere, AA1
Ridge, JA1
Jones, C1
Horwitz, EM1
Glisson, BS1
Nabell, L1
Cooper, JS1
Demas, W1
Gore, E1
Brockstein, B5
Wenig, B5
Weichselbaum, RW2
Faivre, S1
Marti, A1
Rixe, O1
Gatineau, M1
Temam, S1
Armand, JP1
Domenge, C2
Luboinski, B2
Raymond, E1
Chmura, SJ1
Milano, MT1
Beitler, JJ3
Smith, RV3
Silver, CE2
Mazumdar, M1
Wadler, S3
Spencer, SA4
Wheeler, RH4
Machtay, M2
Schultz, C2
Spanos, W2
Rotman, M2
Ang, KK1
Mauer, A1
Dekker, A2
Chen, HX1
Lipshutz, H3
Lerner, HJ4
Beckloff, GL2
Pouillart, P1
Palangie, T1
Garcia-Giralt, E1
Jouve, M1
Bataini, JP1
Jaulerry, M1
Brugère, J1
Asselin, B1
Glick, JH1
Zehngebot, LM1
Taylor, SG1
Veronesi, A1
Barzan, L1
Magri, MD1
Tirelli, U1
Galligioni, E1
Trovò, MG1
Tumolo, S1
Comoretto, R1
Grigoletto, E1
Medenica, R1
Alberto, P1
Lehmann, W2
Eisenberger, MA1
Denefrio, J1
Silverman, M1
Lessner, HE1
Cruz, AB1
Perkins, M1
Aust, JB1
Coltman, CA1
Pollard, EB1
Fletcher, WS1
Kennedy, P1
Lehane, DE1
Mira, J1
McCracken, JD1
Sorgen, SD1
Page, CP1
Pendleton, OJ1
Reddy, E1
Sapp, J1
Smith, F1
Mead, GM1
Jacobs, C1
Vogl, SE1
Camacho, F1
Kaplan, BH1
Lerner, H2
Cinberg, J1
Gonzalez, MF1
Valdivieso, JG1
Sartiano, GP1
Stupp, R3
Malone, D2
Levin, J1
Mick, R6
McEvilly, JM2
Aisner, J1
Hiponia, D1
Conley, B1
Jacobs, M1
Gray, W1
Belani, CP1
Moran, W1
Sweeney, P1
Kies, M2
Moran, WJ3
Kozloff, M2
Mittal, B3
Panje, W1
Wong, WW1
Haaz, MC1
Fischel, JL1
Formento, P1
Renée, N1
Etienne, MC1
Milano, G1
List, M3
Tsukuda, M1
Fasanmade, A1
Glisson, B1
Lippman, SM1
Ratain, MJ3
Sulzen, L4
Klepsch, A1
Athanasiadis, I1
Humerickhouse, R2
Haynes, H1
Quish, A1
Kotz, T2
Serrano, M1
Brook, A1
Peters, GE2
Beenken, SW1
Meredith, RF2
Smith, J1
Conner, W1
Salter, MM2
Abraham, S1
Dolan, ME1
Hsieh, YC1
Schaefer, U1
Micke, O1
Schueller, P1
Willich, N1
Eifel, PJ1
Chung, T1
Rademaker, A1
Weichselbaum, R1
De Crevoisier, R1
Wibault, P1
Koscielny, S1
Lusinchi, A1
Bobin, S1
Eschwege, F1
Price, LA1
Hill, BT1
Calvert, AH1
Shaw, HJ1
Hughes, KB1
DeWys, WD1
Goldsmith, MA1
Carter, SK1
Costanzi, JJ1
Loukas, D1
Gagliano, RG1
Griffiths, C1
Barranco, S1
Johnson, CM1
Harmon, JD1
Pannuti, F1
Cricca, A1
Fruet, F1
Burroni, P1
Rossi, AP1
Jenkins, VK1
Ray, P1
Ellis, HN1
Griffiths, CM1
Perry, RR1
Olson, MH1
Hussey, DH2
Abrams, JP1
Panje, WR6
Buffoli, A1
Morrica, B1
Frata, P1
La Face, B1
Gebbia, V1
Gebbia, N1
Russo, A1
Testa, A1
Valenza, R1
Zerillo, G1
Ingria, F1
Spadafora, G1
Rausa, L1
Beckett, M1
Karrison, T1
Weppelmann, B1
Kim, RY1
Schilsky, RL4
Fountzilas, G3
Daniilidis, J3
Sridhar, KS1
Kalogera-Fountzila, A2
Zaramboukas, T1
Sombolos, K1
Destouni-Salem, E1
Vritsios, A3
Tourkantonis, A2
Moormeier, JA1
Egorin, MJ1
Janisch, L1
Hoffman, PC1
Golomb, HM1
Clavel, M1
Ardiet, JM1
Gignoux, B1
Abele, R2
Honegger, HP2
Wolfensberger, M2
Grossenbacher, R2
Mermillod, B2
Cavalli, F2
Kaplan, E1
Gervasi, A1
Apostolidis, T1
Nicolaou, A1
Sridhar, K1
Sideras, T1
Haritanti, A1
Anastasakis, C1
Delis, V1
Awan, AM2
Goldman, MD1
Tybor, AG1
Guarnieri, CM1
Dodion, P1
Cognetti, F1
van Rymenant, M1
Dalesio, O1
Kirkpatrick, A1
Rozencweig, M1
Boerrigter, GH1
Heinerman, EC1
Braakhuis, BJ1
Snow, GB1
Sullivan, RD1
Bertino, JR1
Mosher, MB1
DeConti, RC1
Simmonds, WP1
Marchetta, FC1
Stephens, FO1
Goffinet, DR1
Bagshaw, MA1
Richards, GJ2
Chambers, RG2
Stefani, S1
Eells, RW1
Abbate, J1
Scherer, E1
Rassow, J1
Samuels, ML1
Godwin, MC1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415]54 participants (Anticipated)Interventional2022-06-22Active, not recruiting
A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782]Phase 240 participants (Anticipated)Interventional2019-05-01Recruiting
A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887]Phase 3236 participants (Anticipated)Interventional2015-06-30Active, not recruiting
Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)[NCT05517330]Phase 223 participants (Anticipated)Interventional2022-12-20Recruiting
Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278]60 participants (Anticipated)Interventional2013-06-30Recruiting
Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00462735]Phase 233 participants (Actual)Interventional2007-02-28Completed
The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309]26 participants (Actual)Interventional2007-06-30Completed
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528]Phase 230 participants (Anticipated)Interventional2021-06-06Recruiting
Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03047265]Phase 2164 participants (Anticipated)Interventional2017-02-04Active, not recruiting
A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol[NCT06087614]Phase 2124 participants (Anticipated)Interventional2023-10-31Recruiting
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502]Phase 1/Phase 215 participants (Actual)Interventional2007-02-28Completed
Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck[NCT00002951]Phase 253 participants (Actual)Interventional1996-06-30Completed
Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658]Phase 250 participants (Actual)Interventional2013-09-30Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]Phase 1/Phase 230 participants (Actual)Interventional2002-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Distant Metastases

Percentage of participants who did not have distant control (NCT00462735)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Advanced Head and Neck Cancer21

Llocoregional Recurrence

Percentage of Participants with Loco-regional recurrence. (NCT00462735)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Advanced Head and Neck Cancer27

Long- Term Toxicity

Grade 3 toxicities events (NCT00462735)
Timeframe: 2 years

Interventionevents (Number)
Advanced Head and Neck Cancer32

UW-QOLR: Quality of Life Score

University of Washington Quality of Life (UW-QOLR) questionnaire - covers 12 domains - pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood and anxiety. Each domain have between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response and reported as one composite score from 0 (worst) to 100 (best). (NCT00462735)
Timeframe: 2 years

Interventionunits on a scale (Mean)
Advanced Head and Neck Cancer80

Survival

Overall Survival - Percentage of Participants who survived Disease-Free Survival - measured from the initiation of nonsurgical treatment to either the last follow-up, disease progression, or death using intent-to-treat methodology (NCT00462735)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Overall SurvivalDisease-Free Survival
Advanced Head and Neck Cancer8669

Toxicity

Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS

Interventionparticipants (Number)
Celecoxib 200mg0
Celecoxib 400mg1
Celecoxib 600mg2

Clinical Response

Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months

InterventionParticipants (Count of Participants)
Complete Response(CR)Pathologic partial response (pPR)Progressive disease (PD)No evidence of disease (NED)
Erlotinib + Celecoxib6152

Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity

At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year

Interventionpercentage of participants (Number)
locoregional controlprogress-free survivaloverall survival rateslong term toxicity
Erlotinib + Celecoxib6037550

Locoregional Progression

Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months

Interventionparticipants (Number)
free of diseaseisolated locoregional progressionisolated distant progressionboth locoregional and distant progressionno evidence of disease, died of comorbid illness
Erlotinib + Celecoxib44213

Response as Evaluated by Recurrence of Diseases

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

InterventionParticipants (Number)
Local Control OnlyLocal Control and Distant MetastasisDistant Metastatsis OnlySecondary Primary - Site UnknownSurgical Salvage
Recurrence62123

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Interventionparticipants (Number)
HematologicDermatitisMucositis/Dysphagia
Acute Toxicity12716

Reviews

14 reviews available for hydroxyurea and Cancer of Head

ArticleYear
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
    The oncologist, 2003, Volume: 8, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2003
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
    American journal of otolaryngology, 1980, Volume: 1, Issue:4

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic;

1980
Changing role of chemotherapy in treatment of head and neck cancer.
    The American journal of medicine, 1982, Volume: 73, Issue:4

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl

1982
The role of paclitaxel in the treatment of head and neck cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

1995
Fluorouracil modulation in head and neck cancer.
    Advances in experimental medicine and biology, 1993, Volume: 339

    Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms;

1993
Combined modalities in the treatment of head and neck cancers.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali

1995
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1995
[Chemoradiotherapy for patients with advanced head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co

1997
Oral 5-FU alternatives for the treatment of head and neck cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10 Suppl 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1998
Chemoradiation for carcinoma of the cervix: advances and opportunities.
    Radiation research, 2000, Volume: 154, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A

2000
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
    Canadian journal of otolaryngology, 1975, Volume: 4, Issue:2

    Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms;

1975
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
    Cancer treatment reviews, 1975, Volume: 2, Issue:2

    Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro

1975
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
    International journal of clinical pharmacology research, 1985, Volume: 5, Issue:4

    Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck

1985
Clinical use of radiation sensitizing agents.
    Cancer treatment reviews, 1974, Volume: 1, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura

1974

Trials

40 trials available for hydroxyurea and Cancer of Head

ArticleYear
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2008
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem

2008
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Cancer, 2011, Jan-15, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Cancer, 2011, Jan-15, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Cancer, 2011, Jan-15, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Cancer, 2011, Jan-15, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2011
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
    Oncology reports, 2012, Volume: 27, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2012
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2013
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
    Head & neck, 2003, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2003
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2003
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2004
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2004
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2004
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2004
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

2006
Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase in
    Head & neck, 2007, Volume: 29, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, R

2007
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Head & neck, 2008, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2008
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
    Cancer investigation, 2007, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe

2007
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-01, Volume: 26, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2008
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
    American journal of otolaryngology, 1980, Volume: 1, Issue:4

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic;

1980
Combination chemotherapy with bleomycin and hydroxyurea in the treatment of advanced head and neck cancer.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Ambulatory Care; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Therapy, Combin

1982
Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma.
    Oncology, 1984, Volume: 41, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin

1984
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

1994
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit

1995
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
    International journal of radiation oncology, biology, physics, 1994, Apr-30, Volume: 29, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

1994
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F

1996
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1997
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

1998
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat

1998
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.
    Investigational new drugs, 1998, Volume: 16, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Dos

1998
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

1999
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

1999
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre

2000
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo

2000
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

2001
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
    Cancer, 2001, Jun-01, Volume: 91, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2001
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
    International journal of radiation oncology, biology, physics, 2001, Dec-01, Volume: 51, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T

2001
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
    Journal of the National Cancer Institute, 1992, Jun-03, Volume: 84, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp

1992
[Chemo-radiotherapy in advanced head and neck tumors. Personal experience].
    La Radiologia medica, 1992, Volume: 83, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cobalt Radioisotopes; Combin

1992
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc

1991
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M

1992
A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1987
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
    Archives of oto-rhino-laryngology, 1989, Volume: 246, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam

1989
Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients.
    Radiology, 1971, Volume: 101, Issue:2

    Topics: Adult; Clinical Trials as Topic; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle

1971

Other Studies

54 other studies available for hydroxyurea and Cancer of Head

ArticleYear
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2022, Jan-01, Volume: 48, Issue:1

    Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R

2022
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
    Radiation oncology (London, England), 2015, Apr-18, Volume: 10

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino

2015
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
    BMC cancer, 2016, 07-13, Volume: 16

    Topics: Alanine; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Azoles; B

2016
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
    Cancer medicine, 2017, Volume: 6, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2017
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
    The Journal of laryngology and otology, 2009, Volume: 123, Issue:8

    Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy

2009
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
    Cancer, 2011, Oct-15, Volume: 117, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch

2011
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2003
Development of cross-resistance between heat and cisplatin or hydroxyurea treatments in FaDu squamous carcinoma cells.
    The Journal of surgical research, 2003, May-01, Volume: 111, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Drug Resistance, Neoplasm

2003
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2003
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com

2004
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Head & neck, 2005, Volume: 27, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2005
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality

2006
Hydroxyurea in the management of head and neck cancer. II. Surgical aspects.
    Plastic and reconstructive surgery, 1967, Volume: 40, Issue:3

    Topics: Antineoplastic Agents; Head; Head and Neck Neoplasms; Humans; Hydroxyurea; Mandibular Neoplasms; Neo

1967
[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)].
    Bulletin du cancer, 1980, Volume: 67, Issue:3

    Topics: Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Head and Neck

1980
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
    Strahlentherapie, 1981, Volume: 157, Issue:4

    Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N

1981
Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea.
    Cancer chemotherapy and pharmacology, 1981, Volume: 5, Issue:3

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Head and Neck

1981
Concurrent chemotherapy and radiation therapy of selected head and neck squamous cell carcinomas using bleomycin and hydroxyurea: A Southwest Oncology Group Study.
    Journal of surgical oncology, 1982, Volume: 20, Issue:4

    Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combin

1982
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity.
    Cancer, 1983, Dec-01, Volume: 52, Issue:11

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug

1983
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:1

    Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce

1996
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
    American journal of clinical oncology, 1999, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo

1999
Pharyngeal transport dysfunction consequent to an organ-sparing protocol.
    Archives of otolaryngology--head & neck surgery, 1999, Volume: 125, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Deg

1999
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
    Radiology, 2000, Volume: 216, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Kinetically-based multiple drug treatment for advanced head and neck cancer.
    British medical journal, 1975, Jul-05, Volume: 3, Issue:5974

    Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla

1975
Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies: a preliminary report.
    Cancer, 1976, Volume: 38, Issue:4

    Topics: Adult; Bleomycin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Therapy, Combination;

1976
Head and neck neoplasms: outpatient chemotherapy.
    Ear, nose, & throat journal, 1979, Volume: 58, Issue:2

    Topics: Ambulatory Care; Head and Neck Neoplasms; Humans; Hydroxyurea; Methotrexate

1979
New polychemotherapy regimen for head and neck tumors: pilot study.
    Cancer treatment reports, 1979, Volume: 63, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration

1979
Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania hospital.
    American journal of surgery, 1977, Volume: 134, Issue:4

    Topics: Carcinoma, Squamous Cell; Cell Division; Cell Line; DNA, Neoplasm; Head and Neck Neoplasms; Humans;

1977
Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy.
    Archives of otolaryngology (Chicago, Ill. : 1960), 1976, Volume: 102, Issue:10

    Topics: Concanavalin A; Head and Neck Neoplasms; Humans; Hydroxyurea; Lectins; Leukocyte Count; Lymphocyte A

1976
Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy.
    Progress in clinical cancer, 1975, Volume: 6

    Topics: Head and Neck Neoplasms; Humans; Hydroxyurea; Pilot Projects; Radiotherapy

1975
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
    Anti-cancer drugs, 1992, Volume: 3, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul

1992
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
    Oncology, 1992, Volume: 49, Issue:6

    Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea

1992
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:5

    Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and

1992
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
    The Laryngoscope, 1992, Volume: 102, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb

1992
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:3 Suppl 9

    Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H

1992
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
    Cancer, 1990, Oct-01, Volume: 66, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1990
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu

1991
Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK).
    Progress in clinical and biological research, 1985, Volume: 201

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1985
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
    Laryngologie, Rhinologie, Otologie, 1988, Volume: 67, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam

1988
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino

1989
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1988, Volume: 98, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1988
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati

1986
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
    British journal of cancer, 1986, Volume: 54, Issue:1

    Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance

1986
Chemotherapy in head and neck cancer.
    JAMA, 1971, Jul-26, Volume: 217, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Arteries; Carcinoma, Squamous Cell; Head; Head and Neck

1971
Chemotherapy of cancer of the head and neck.
    Cancer, 1973, Volume: 31, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Catheteriza

1973
Chemotherapy in recurrent heat and neck cancer.
    Otolaryngologic clinics of North America, 1974, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera

1974
Proceedings: Carcinoma of the oral cavity--general principles of therapy.
    Journal of surgical oncology, 1974, Volume: 6, Issue:4

    Topics: Azirines; Bleomycin; Carcinoma, Squamous Cell; Cryosurgery; Dactinomycin; Doxorubicin; Head and Neck

1974
Combined chemotherapy, radiotherapy, and surgery in the treatment of advanced but localized solid malignant tumours.
    The Australian and New Zealand journal of surgery, 1974, Volume: 44, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cystadenocarcinoma; Drug Th

1974
Hydroxyurea in the treatment of neoplasms of the head and neck. A resurvey.
    American journal of surgery, 1973, Volume: 126, Issue:4

    Topics: Administration, Oral; Ear Neoplasms; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hydroxyurea

1973
Six year survival in the combined treatment of far advanced head and neck cancer under a combined therapy program.
    American journal of surgery, 1973, Volume: 126, Issue:4

    Topics: Carcinoma, Squamous Cell; Evaluation Studies as Topic; Head and Neck Neoplasms; Humans; Hydroxyurea;

1973
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
    Strahlentherapie, 1971, Volume: 141, Issue:5

    Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N

1971
Combined hydroxyurea and radiotherapy: a new dosage schedule.
    Southern medical journal, 1972, Volume: 65, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms;

1972
Three-year observation of combined treatment for far advanced cancer of the head and neck.
    American journal of surgery, 1969, Volume: 118, Issue:5

    Topics: Carcinoma, Squamous Cell; Head; Head and Neck Neoplasms; Humans; Hydroxyurea; Mouth Neoplasms

1969
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1969, Volume: 105, Issue:3

    Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo

1969
Concomitant hydroxyurea and radiotherapy in the management of 60 patients with head and neck cancer.
    The American surgeon, 1969, Volume: 35, Issue:7

    Topics: Adult; Aged; Female; Gingival Diseases; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Maxillar

1969